Document   

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_____________________________________________________________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934 

______________________________________________________________________

Date of Report (Date of earliest event reported): January 29, 2019

BOSTON SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

[DATA_TABLE_REMOVED]

300 Boston Scientific Way, Marlborough, Massachusetts01752-1234

(Address of principal executive offices)(Zip code)

Registrant's telephone number, including area code: (508) 683-4000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

oWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

Emerging growth company o 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

ITEM 8.01. OTHER EVENTS.

On January 29, 2019, Boston Scientific Corporation (the “Company”) completed its acquisition of Millipede, Inc. (“Millipede”) following the expiration of the applicable waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended. The Company previously announced the entry into an acquisition option agreement with Millipede on January 24, 2018 and the exercise of such acquisition option on December 27, 2018. Millipede has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

[DATA_TABLE_REMOVED]